BenzingaOctober 14, 2026 at 3:05 AM NY13 Days Ago
Invivyd And SPEAR Study Group Initiate FLINTLOCK Phase 2 Trial Evaluating Safety, Tolerability, Pharmacokinetics, And Clinical Efficacy Of High-Dose Monoclonal Antibody VYD2311 In Individuals With Long COVID Or Post-Vaccination Syndrome
The Phase 2 FLINTLOCK clinical trial includes the following study features:Randomized, double-blind, placebo-controlled, proof-of-concept studyTests Invivyd’s monoclonal antibody VYD2311, an investigational monoclonal
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
